Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.
作者信息
Mohan Meera, Janz Siegfried, Brazauskas Ruta, Dwinell Michael B, Teng Bi Qing, Yun Grant, Dong Jing, Pasquini Marcelo C, Giralt Sergio, Landau Heather, Stadtmauer Edward, Krishnan Amrita, D'Souza Anita
机构信息
Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
出版信息
Bone Marrow Transplant. 2023 Aug;58(8):953-955. doi: 10.1038/s41409-023-02004-5. Epub 2023 May 6.
Abstract
摘要
相似文献
1
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.在接受来那度胺维持治疗的多发性骨髓瘤患者中，自体造血细胞移植1年后可观察到CXCL10升高。
Bone Marrow Transplant. 2023 Aug;58(8):953-955. doi: 10.1038/s41409-023-02004-5. Epub 2023 May 6.
2
Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤自体干细胞移植后维持治疗的真实世界疗效
BMC Cancer. 2025 Feb 5;25(1):204. doi: 10.1186/s12885-025-13518-0.
3
Risk adapted post-transplant maintenance in multiple myeloma.多发性骨髓瘤的风险适应性移植后维持治疗。
Expert Rev Hematol. 2019 Feb;12(2):107-118. doi: 10.1080/17474086.2019.1576521.
4
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.适合自体移植的初诊多发性骨髓瘤患者维持治疗策略的进展。
Expert Rev Hematol. 2020 Dec;13(12):1333-1347. doi: 10.1080/17474086.2020.1839886. Epub 2020 Oct 26.
5
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.多发性骨髓瘤患者自体干细胞移植后硼替佐米维持治疗的结果
Biol Blood Marrow Transplant. 2017 Feb;23(2):262-268. doi: 10.1016/j.bbmt.2016.11.010. Epub 2016 Nov 14.
6
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
7
Lenalidomide maintenance in Myeloma - a goldilocks problem?来那度胺用于骨髓瘤维持治疗——是个“金发姑娘”问题吗？
Leuk Lymphoma. 2023 Oct;64(10):1611-1614. doi: 10.1080/10428194.2023.2255325. Epub 2023 Sep 6.
8
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.加拿大来那度胺治疗多发性骨髓瘤后的治疗模式和结局的回顾性研究。
Eur J Haematol. 2021 Oct;107(4):416-427. doi: 10.1111/ejh.13678. Epub 2021 Jun 27.
9
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.来那度胺与硼替佐米维持治疗多发性骨髓瘤自体造血干细胞移植后的选择。
Bone Marrow Transplant. 2018 Jun;53(6):701-707. doi: 10.1038/s41409-018-0177-6. Epub 2018 Apr 27.
10
Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.来那度胺维持治疗继第二次自体干细胞移植后可改善多发性骨髓瘤的总生存期。
Leuk Lymphoma. 2020 Aug;61(8):1877-1884. doi: 10.1080/10428194.2020.1749603. Epub 2020 Apr 9.
本文引用的文献
1
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.多发性骨髓瘤自体造血细胞移植后生活质量恢复和症状负担的轨迹。
Am J Hematol. 2023 Jan;98(1):140-147. doi: 10.1002/ajh.26596. Epub 2022 May 21.
2
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.自体移植、巩固和维持治疗多发性骨髓瘤：BMT CTN 0702 试验结果。
J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17.
3
High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma.
Leuk Lymphoma. 2017 Oct;58(10):2493-2496. doi: 10.1080/10428194.2017.1295144. Epub 2017 Feb 28.
4
Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.干扰素γ诱导的单核细胞趋化蛋白（MIG/CXCL9）是新诊断骨髓瘤的独立预后因素。
Leuk Lymphoma. 2016 Nov;57(11):2516-25. doi: 10.3109/10428194.2016.1151511. Epub 2016 Mar 21.
5
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.来那度胺在多发性骨髓瘤维持治疗中对免疫功能的影响。
Leukemia. 2015 Oct;29(10):2098-100. doi: 10.1038/leu.2015.64. Epub 2015 Mar 9.
6
Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.多发性骨髓瘤患者自体干细胞移植后患者报告症状的纵向分析及其与炎症的关系。
Leuk Lymphoma. 2015 May;56(5):1335-41. doi: 10.3109/10428194.2014.956313. Epub 2014 Nov 20.
7
Heparanase enhances myeloma progression via CXCL10 downregulation.乙酰肝素酶通过下调CXCL10促进骨髓瘤进展。
Leukemia. 2014 Nov;28(11):2178-87. doi: 10.1038/leu.2014.121. Epub 2014 Apr 4.
8
Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation.自体干细胞移植期间多发性骨髓瘤患者的炎症标志物与症状负担的发展
Clin Cancer Res. 2014 Mar 1;20(5):1366-74. doi: 10.1158/1078-0432.CCR-13-2442. Epub 2014 Jan 14.
9
The systemic cytokine environment is permanently altered in multiple myeloma.多发性骨髓瘤患者的全身细胞因子环境会发生永久性改变。
PLoS One. 2013;8(3):e58504. doi: 10.1371/journal.pone.0058504. Epub 2013 Mar 27.
10
Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life.患有晚期但稳定的多发性骨髓瘤：研究疾病的症状负担和累积效应以及强化（基于造血干细胞移植的）治疗对健康相关生活质量的影响。
J Pain Symptom Manage. 2013 Nov;46(5):671-80. doi: 10.1016/j.jpainsymman.2012.11.003. Epub 2013 Mar 25.
Zotero 插件